Cardiovascular Drug Therapy in the Elderly (Developments in Cardiovascular Medicine)

個数:

Cardiovascular Drug Therapy in the Elderly (Developments in Cardiovascular Medicine)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 386 p.
  • 言語 ENG
  • 商品コード 9781461292258
  • DDC分類 616

Full Description

Cardiovascular drug therapy has markedly progressed in the recent decades. Not only have new drugs been introduced to clinical practice, but new classes of drugs have been developed. While in 1960 the practicing cardiolo­ gist had a selection of about only ten drugs, in 1987 about 150 drugs are routinely used in cardiovascular diseases. Elderly patients, however, usually do not enjoy the full benefit of this progress. This might be due to lack of knowledge, a conservative approach, or the worldwide tendency not to try new drugs in the elderly. It is now clear that the majority of patients that will be treated in car­ diovascular clinics will be, in the near future, elderly patients. Even now, elderly patients form about one-third of the patients with cardiovascular diseases. These patients are approached, however, according to criteria devel­ oped for younger populations. This is despite the fact that elderly patients differ from younger ones in most aspects, including pathology, epidemiol­ ogy, pathophysiology, diagnostic approach, management, pharmacology, pharmacokinetics, rehabilitation, and supportive treatment. It is the purpose of this book to present to the clinician all drugs with which there is clinical experience in the elderly or which might be potentially useful for the elderly with cardiovascular diseases. The data are presented without the authors taking a position. This should allow the clinicians to make their own selection and individualize treatment, vii viii Preface based on a wide data base. Comparative data are presented only when specific comparative studies were performed.

Contents

I. Agents Directly Enhancing Myocardial Contractility.- 1. Introduction.- 2. Digitalis glycosides.- 3. Bipyridine derivatives.- 4. Dobutamine.- 5. Dopamine.- 6. MDL-17,043 (Piroximone).- 7. Ibopamine.- II. Vasodilators.- 8. Introduction.- 9. Captopril.- 10. Enalapril.- 11. Enalaprilat.- 12. Nifedipine.- 13. Nitrendipine.- 14. Verapamil.- 15. Diltiazem.- 16. Prazosin.- 17. Urapidil.- 18. Nitrates.- 19. Nitroprusside.- 20. Hydralazine.- 21. Endralazine.- 22. Minoxidil.- III. Antiarrhythmic Drugs.- 23. Introduction.- 24. Quinidine.- 25. Disopyramide.- 26. Lidocaine.- 27. Tocainide.- 28. Lorcainide.- 29. Propafenone.- 30. Mexiletine.- 31. Ethmozine.- 32. Encainide.- 33. Amiodarone.- 34. Adenosine.- IV. Beta-Adrenoreceptor Blockers.- 35. Introduction.- 36. Propranolol.- 37. Atenolol.- 38. Metoprolol.- 39. Oxprenolol.- 40. Alprenolol.- 41. Sotalol.- 42. Esmolol.- V. Centrally Acting Antihypertensive Agents.- 43. Introduction.- 44. Methyldopa.

最近チェックした商品